Australian Synthetic Antibiotic Succeeds Against Superbugs Where Others Fail
Announcement posted by Marko Communications 14 Oct 2015
Good morning
I want to alert you today, to an exciting breakthrough and great discovery!
What is so exciting about this, is that the discovery addresses “one of the greatest threats to human health today”[1] – superbugs. The discovery, potentially saving millions of lives.
And it’s an Australian Company, Recce Ltd that has achieved what no one else in the world has been able to do.
Until Recce, no one else had wholly synthetised an entirely new antibiotic – different from anything previous – designed, and superior to existing antibiotics - able to keep on killing disease-causing germs without falling to antibiotic resistance. Widely effective over all types of bacteria as well as superbugs.
The company is Recce Ltd.
Dr Graham Melrose and the scientists at Recce are leading the world fight against MRSA and other antibiotic resistant superbugs.
By producing patented, wholly synthetic, man-made antibiotics.
Most antibiotics are produced from natural sources (e.g. fungi). These natural antibiotics have been over-used which has allowed bacteria to build-up resistance after mutating into more dangerous, superbug forms. By constructing a synthetic antibiotic, designed by the research group to avoid resistance developing, has resulted in the first new class of antibiotic for humans, in 40 years.
RECCE antibiotics have demonstrated in the laboratory – and now in tests within mice, to be effective against a wide range of Gram-positive and Gram-negative bacteria, including their superbug forms – and to keep on killing even after repeated use. This is where many commercial antibiotics are failing – and RECCE antibiotics have succeeded.
The scope and measure of the potential benefits are enormous.
The company is in pre-clinical testing of the following human health needs:
Bacterial Sepsis
Worldwide annual deaths from sepsis are estimated in the tens of millions; in the United States, Sepsis kills more people than colon cancer, breast cancer and HIV/AIDS combined.
Sepsis strikes an estimated 30 million people worldwide every year. Sepsis is a global health problem that carries a high risk of death - over one-third of these patients die without leaving hospital. Underlying infection is treated with, most commonly, broad-spectrum anti-bacterials in U.S. hospitals costing more than $20 billion in 2011.
Escherichia coli derived diarrhoea
20% to 50% of all travellers develop diarrhoea mostly attributable to enterotoxic E. coli. There are an estimated 1.7 billion cases of diarrhoeal disease every year which are responsible for killing around 760,000 children under 5 years every year.
Helicobacter pylori derived gastritis
H. pylori, present in 20% to 90% of persons worldwide, is one of the world’s most prevalent pathogenic bacteria; it is very strongly associated with human gastritis, peptic ulcers and gastric cancer; H. pylori is a major factor in virtually all patients with duodenal ulcers, and approximately 70% with gastric ulcers.
The Hon. Malcolm Turnbull, MP, Prime Minister of Australia, recently announced that he desired to bring a new future to Australia through innovation.
This discovery is ground breaking and a world-first.
For further details of the process and results of trials to date please go to www.recce.com.au or contact:
Karen Oswald
Marko Communications
Tel: 0423 602 353
Email: Karen.oswald@markocommunications.com.au
Or
Gary Buchholz
Marko Communications
Tel: 0412 88 45 45